Clinical Data — Fifth Annual Noble Financial Equity Conference 2009
23 slides from Clinical Data's conference presentation, Jun 9, 2009
Slide 1: Fifth Annual Noble Financial Equity Conference
1 Fifth Annual Noble Financial Equity Conference June 9, 2009
Slide 2: Forward-Looking Statement
Forward-Looking Statement 2 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements a
Slide 3: Investment Opportunity
Investment Opportunity Clinical Data is a biotechnology company developing late-stage drugs that are first-in-class, best-in-category, or both 3 High-margin products Product differentiation Lower technical risk Reduced development expense Intellectual property protection
Slide 4: Disease Areas
Disease Areas Central Nervous System Depression Pain (chronic and acute) Cardiovascular Disease Stress test imaging Inherited cardiac conditions, e.g., Long QT Syndrome Oncology Non-Hodgkin's lymphoma Breast cancer Colorectal cancer 4
Slide 5: Current Value Drivers
Current Value Drivers Two Phase III drugs: Vilazodone(tm): first in new class of dual acting serotonergic antidepressants Stedivaze(tm): potential best-in-class drug used during cardiac stress imaging Deep pipeline of drug (Rx) and diagnostic (Dx) candidates Genetic testing business for inherited ca
Slide 6: Depression Market
Depression Market Major Depressive Disorder is the leading cause of disability in the U.S. for ages 15-44 Depression affects approximately 18M U.S. adults Antidepressants are largest segment of U.S. CNS market ~$12B annual sales 208M+ prescriptions with ~4% CAGR Cost of depression estimated to be $8
Slide 7: Prescription Usage by Treatment Source
Prescription Usage by Treatment 7 Source: IMS NDTI MAT 9/06
Slide 8: Relevant Market Rx's
8 Relevant Market* Rx's ('000s) Source: IMS Health's National Prescription Audit * Relevant market includes SSRIs, SNRIs, and Wellbutrin 3.6% CAGR
Slide 9: Vilazodone for Major Depression
Vilazodone for Major Depression Current drugs are limited Response may take weeks to determine Common side effects include gastrointestinal, sexual dysfunction and weight gain Co-morbid conditions are common and often require treatment with concomitant medications Poor compliance 2/3 of patients do
Slide 10: Vilazodone Positive Top-line Phase III Results
Vilazodone Positive Top-line Phase III Results 2nd Phase III trial confirmed findings from 1st Phase III study Achieved primary and secondary endpoints related to depression Statistically significant reduction in depression symptoms as measured by two independent rating scales P= 0.007 MADRS P= 0.02
Slide 11: Vilazodone Positive Top-line Phase III Results
Vilazodone Positive Top-line Phase III Results No difference in sexual dysfunction compared to placebo, as measured by two validated scales in Phase III studies Generally well tolerated Most common adverse events were diarrhea, nausea and headache Discontinuation rate due to adverse events was 4.3%
Slide 12: Market Research Confirms Significant Potential of Vilazodone
Market Research Confirms Significant Potential of Vilazodone Quantitative, primary market research with PCPs & psychiatrists Physicians achieved desired results with 1st line treatment only 50% of time or less Tolerability is primary reason in 25% of patients discontinuations Almost 60% (65% of psyc
Slide 13: Vilazodone Development Milestones
Vilazodone Development Milestones Completed our Phase III program with positive results Long-term safety study completed Exceeded threshold of 100 patients on drug for 12 months Commercial scale-up successful NDA filing anticipated by year end 2009 13
Slide 14: Stedivaze: Vasodilator for Cardiac Stress Imaging
Stedivaze: Vasodilator for Cardiac Stress Imaging Stedivaze: Vasodilator for Cardiac Stress Imaging 14 1 AMR Monthly Monitor
Slide 15: Phase II Results: Stedivaze AE Profile is Better than Adenoscan
Phase II Results: Stedivaze AE Profile is Better than Adenoscan Hendel et al AHA, 2005 *Safety population only. Incidence of AEs 5% or greater. 15 Dyspnea Chest Pain Dizziness Headache Flushing Hypotension Nausea 2° AV Block % with AEs Adenoscan 0 20 40 N = 124 Stedivaze (Apadenoson) 1.0 ^g/kg 2.0 ^
Slide 16: Stedivaze Development Milestones
Stedivaze Development Milestones Successful end-of-Phase II meeting with FDA Consensus on overall trial design and use of fixed dose regimen Clarified extent of other common program requirements to be considered for the NDA submission Launching Phase III clinical program Phase III protocol submitted
Slide 17: Our Therapeutics Pipeline
Our Therapeutics Pipeline Current Stage Lead Discovery Preclinical Phase I Phase II Phase III NDA Marketed Novartis Confidential Partner Vilazodone(tm) Major Depression Stedivaze(tm) Cardiac Imaging ATL1222: Acute Inflammation ATL844: Diabetes / Asthma ATL313 : Ophthalmic Pain AVN316: Oncology Proje
Slide 18: Acquisition of Avalon Pharmaceuticals
Acquisition of Avalon Pharmaceuticals Expands capabilities in oncology Rx and Dx Drug discovery platform to identify targets in historically "undruggable" pathways Initial focus on Beta-catenin program Significant pharma interest in platform's capabilities, new targets and pathways 18
Slide 19: Dx for Inherited Cardiac Conditions: FAMILION
Dx for Inherited Cardiac Conditions: FAMILION(r) Over 100% Growth Year Over Year* 19 *Calendar Year 0 ..5 1 1.5 2 2.5 2004 2005 2006 2007 2008 New Sales Force $ (Millions) $3
Slide 20: Dx for Drug Response: PGxPredict: RITUXIMAB
Dx for Drug Response: PGxPredict(r):RITUXIMAB 20 FCGR3A variant is important in determining individual response to IgG1 mAbs Efficient Cell Death Poor Cell Death Dall'Ozzo S, Tartas S, Paintaud G, et al, Cancer Research, 64:4664-4669 FCGR3A IgG1 MAb NK, Macrophage Tumor Cell FCGR3A IgG1 MAb NK, Macr
Slide 21: Clinical Data (CLDA) Profile
Clinical Data (CLDA) Profile* Market Cap: $271.1M (as of 6/5) Revenue**: $10.1M (3 mo.) $28.2M (9 mo.) Cash & Marketable Securities: $28.4M $50.0M Convertible debt financing (2/26) $15.1M Sale of Cogenics service business (4/15) Debt: $27.2M Insider Ownership: ~ 50% Substantially all shares purchase
Slide 22: Upcoming Milestones in 2009
Upcoming Milestones in 2009 Initiate Phase III program for Stedivaze File vilazodone NDA with the FDA Obtain additional positive reimbursement policies for our genetic testing business Establish partnerships for other preclinical programs Potential to receive additional milestone payment from existi
Slide 23: Thank You
> TeX. From Targeted Science y bh O a » j ~ to Beiter Healthcare™ & & , CLINICAL ?## DATA® Thank You
Clinical Data — Fifth Annual Noble Financial Equity Conference 2009 on 6ix